All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 30, 2022
Home » Blogs » BioWorld Perspectives » No joy in Bio-ville

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

No joy in Bio-ville

Dec. 30, 2015
By Mari Serebrov
No Comments

GrinchWhether naughty or nice in 2015,

Drugmakers received not what they wanted

And not what they needed,

For the biggest “must-haves” on their wish list

Went mostly unheeded.

 

At the top of that list, and repeated quite often,

Was a gift to undo the threat to their patents

From that monster of monsters, the IPR Grinch.

But 2015 came and is going,

with no help in sight, no relief from a mensch.

 

Second in line, but no less desired,

Was prayer for relief

From a CMS mire.

Part B biosimilars must not – no, they must NOT  –

Be reimbursed by this ill-conceived plot.

 

Despite the loud voices, and the many demands,

CMS said, “Think what you like.

We’re not backing down.

Besides, there’s only one

Biosimilar in all of the town.”

 

Third on the list, a question arises.

“Where are the guidances the FDA promised –

On labeling, switching and extrapolating?

We’ve a market to create. We’re in a crisis.

How much longer will we be waiting?

 

“Yes, there was one, albeit a draft,

But it was not to our liking. No, it was NOT.

While it has problems aplenty, on this we agree:

Biosimilar names mustn’t be meaningless, too long or too strange.

This guidance is in need of some definite change.”

 

Also important, but also ignored,

Were requests for much-needed tax reforms.

So to keep what they make and profit more freely,

Drugmakers moved across the wide sea. Twas only in name,

And out of frustration with the same-old, same-old IRS game.

 

So goodbye to 2015

And the gifts unreceived.

Say hello to 2016.

May much more be achieved.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 29, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for June 29.
  • Enhertu.png

    Swing low, sweet Enhertu: Astrazeneca, Daiichi ASCO data carry HER2 message home

    BioWorld
    The “showdown” at the American Society of Clinical Oncology (ASCO) meeting foreseen by one analyst between breast cancer drugs from Gilead Sciences Inc. and...
  • Novavax-COVID-19-vaccine-vial

    Novavax vaccine shows its chops

    BioWorld
    Given that Novavax Inc.’s COVID-19 vaccine will be a latecomer to the U.S. scene if it gets FDA authorization, it’s been cast in a supporting role to the lead...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing